Article
Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Cancer immunology, immunotherapy : CII - 1 Apr 2013
Ott Patrick A, Henry Trevor, Baranda Sonja Jimenez, Frleta Davor, Manches Olivier, Bogunovic Dusan, Bhardwaj Nina
Abstract excerpt
PURPOSE: Dendritic cells (DCs) can induce strong tumor-specific T-cell immune responses. Constitutive upregulation of the mitogen-activated protein kinase (MAPK) pathway by a BRAF(V600) mutation, which is present in about 50 % of metastatic melanomas, may be linked to compromised function of DCs in the tumor microenvironment. Targeting both MEK and BRAF has shown efficacy in BRAF(V600) mutant melanoma. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.